Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15742427 | 0.84 | RAB9A (0.42) | RAB9ANPC1SMN1; SMN2HPGDPKM | |
| SCHEMBL6883125 | 0.84 | CXCR4 (0.42) | RAB9ANPC1SMN1; SMN2HPGDPKM | |
| SCHEMBL15742852 | 0.82 | RAB9A (0.40) | RAB9ANPC1SMN1; SMN2HPGDPKM | |
| SCHEMBL6878662 | 0.82 | CXCR4 (0.41) | RAB9ANPC1SMN1; SMN2HPGDPKM | |
| SCHEMBL6439248 | 0.82 | CXCR4 (0.41) | RAB9ANPC1SMN1; SMN2HPGDPKM | |
| SCHEMBL563422 | 0.78 | NPC1 (0.37) | RAB9ANPC1SMN1; SMN2HPGDPKM | |
| SCHEMBL563917 | 0.73 | RAB9A (0.47) | RAB9ANPC1SMN1; SMN2HPGDPKM | |
| SCHEMBL7139490 | 0.72 | CXCR4 (0.37) | RAB9ANPC1SMN1; SMN2HPGDPKM | |
| SCHEMBL6872828 | 0.71 | CBFB (0.39) | RAB9ANPC1SMN1; SMN2HPGDPKM | |
| SCHEMBL7288146 | 0.71 | POLB (0.45) | RAB9ANPC1SMN1; SMN2HPGDPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211590-B2 | Nitrosated proton pump inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-05-01 | — | — | US | claimed |
| US-6852739-B1 | Methods using proton pump inhibitors and nitric oxide donors | NITROMED INC. (US) | 2005-02-08 | — | — | US | claimed |
| US-20040266828-A1 | Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2004-12-30 | — | — | US | claimed |
| US-20040024014-A1 | Nitrosated proton pump inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2004-02-05 | — | — | US | claimed |
| US-9085508-B2 | Nitric oxide releasing amino acid ester compound, composition and method of use | ORAL DELIVERY TECHNOLOGY LTD. (US) | 2015-07-21 | — | — | US | disclosed |
| EP-2342175-B1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | NITROGENIX INC (VG) | 2015-05-27 | — | — | EP | disclosed |
| US-8846674-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX, S.A. (FR) | 2014-09-30 | — | — | US | disclosed |
| US-20140057873-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | FARBER MICHAEL (US) | 2014-02-27 | — | — | US | disclosed |
| US-20130317094-A1 | USE OF ELLAGITANNINS AS INHIBITORS OF BACTERIAL QUORUM SENSING | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2013-11-28 | — | — | US | disclosed |
| US-20120034321-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. | 2012-02-09 | — | — | US | disclosed |
| US-8067464-B2 | Compositions and methods using apocynin compounds and nitric oxide donors | NITROMED, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067414-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX S.A. (FR) | 2011-11-29 | — | — | US | disclosed |
| WO-2005030135-A2 | NITROSATED GLUTAMIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005023183-A2 | NITROSATED AD NITROSYLATED DIURETIC COMPOUDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| US-20050059655-A1 | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use | NITROMED, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| WO-2005023182-A2 | NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005018561-A2 | NITROSATED AND NITROSYLATED CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2004024186-A2 | TREATMENT OF CYCLOOXYGENASE-3 MEDIATED DISEASES AND DISORDERS | NITROMED, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004012659-A2 | NITROSATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-02-12 | — | — | WO | disclosed |
| US-20040024014-A1 | Nitrosated proton pump inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317094-A1 | USE OF ELLAGITANNINS AS INHIBITORS OF BACTERIAL QUORUM SENSING | QSOX1, QARS1, GMPS | RAB9A 1117/4885NPC1 4668/4885SMN1; SMN2 4856/4885 |
| US-20120034321-A1 | NITRIC OXIDE ENHANCING PROSTAGLANDIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE | PTGIS, NOS2, PTGS1 | RAB9A 2457/4885NPC1 849/4885SMN1; SMN2 1781/4885 |
| US-20040024014-A1 | Nitrosated proton pump inhibitors, compositions and methods of use | NOS1, PTGS1, NOS2 | RAB9A 1040/4885NPC1 1662/4885SMN1; SMN2 4312/4885 |
| US-20050059655-A1 | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use | REN, NOS1, NOS3 | RAB9A 1847/4885NPC1 439/4885SMN1; SMN2 3461/4885 |
| US-20040266828-A1 | Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use | NOS2, NOS1, PTGS2 | RAB9A 990/4885NPC1 3855/4885SMN1; SMN2 4182/4885 |
| US-20140057873-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | NOS2, NOS3, NOS1 | RAB9A 1924/4885NPC1 2683/4885SMN1; SMN2 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.